143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial.

Abstract

143PD Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial O. Gautschi1, Q. Li2, K. Matter-Walstra3, D. Betticher4, M. Frueh5, D. Rauch6, M. Pless7, P. Froesch8, N. Mach9, A. Ochsenbein10. 1Medizinische Onkologie, Luzerner Kantonsspital, Luzern… (More)
DOI: 10.1016/S1556-0864(16)30253-2

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.